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Human cytomegalovirus (HCMV) is the most frequent cause of congenital viral infections in humans and
frequently leads to long-term central nervous system (CNS) abnormalities that include learning disabilities,
microcephaly, and hearing loss. The pathogenesis of the CNS infection has not been fully elucidated and may
arise as a result of direct damage of CMV-infected neurons or indirectly secondary to inflammatory response
to infection. We used a recently established model of mouse CMV (MCMV) infection in newborn mice to
analyze the contribution of humoral immunity to virus clearance from the brain. In brains of MCMV-infected
newborn mice treated with immune serum, the titer of infectious virus was reduced below detection limit,
whereas in the brains of mice receiving control (nonimmune) serum significant amounts of virus were
recovered. Moreover, histopathological and immunohistological analyses revealed significantly less CNS in-
flammation in mice treated with immune serum. Treatment with MCMV-specific monoclonal antibodies also
resulted in the reduction of virus titer in the brain. Recipients of control serum or irrelevant antibodies had
more viral foci, marked mononuclear cell infiltrates, and prominent glial nodules in their brains than mice
treated with immune serum or MCMV-specific antibodies. In conclusion, our data indicate that virus-specific
antibodies have a protective role in the development of CNS pathology in MCMV-infected newborn mice,
suggesting that antiviral antibodies may be an important component of protective immunological responses
during CMV infection of the developing CNS.
Human cytomegalovirus (HCMV) represents the most com-
mon cause of congenital viral infection in humans (41). Symp-
toms associated with congenital HCMV brain disease vary
from mild perceptual deficits such as vision impairment and
hearing loss to severe sequelae including microcephaly, cere-
bral dysplasia, and psychomotor retardation (6, 49). The mech-
anism of CMV-induced neuropathogenesis of CMV infection
has not been elucidated, and it may arise secondary to direct
viral damage to neurons or indirectly because of the host
response to infection. Proposed mechanisms of the disease
include interruption of blood supply to developing brain, mi-
gration deficits of developing neurons, and loss of neural pro-
genitor cells in the subventicular zone due to inflammation
coupled with delays in myelinization (2, 19, 29, 30, 52). Exper-
imental evidence suggests that neurons in the developing brain
are potentially more permissive for CMV infection than ma-
ture ones (22, 34, 59). In addition, susceptibility to murine
CMV (MCMV) infection of central nervous system (CNS)
diminishes with the age of mice, and MCMV infection in
immunocompetent adult mice, in contrast to newborn mice,
does not result in virus dissemination within the CNS (40, 54).
In primary infection, CMV dissemination is considered mostly
cell associated (43, 51), but little is known about the means of
CMV dissemination into the developing CNS.
Both innate and adaptive immune responses play a role in
the control of CMV infection in various organs and tissues
(27). While NK cells and other components of innate immune
response are responsible for containment of primary MCMV
infection during the early period after infection, the compo-
nents of adaptive cellular immune response are essential for
termination of productive virus infection (26). In contrast, an-
tiviral antibodies are dispensable for the resolution of primary
CMV infection and establishment of latency. However, anti-
bodies play a key role in prevention of virus dissemination after
reactivation from latency or reinfection (21, 35). It is generally
accepted that antiviral antibodies mediate their protective ac-
tivity by direct neutralization or indirectly via complement
activation and by promoting antibody-dependent cellular cyto-
toxicity (18). Therefore, it is conceivable that antibodies may
suppress CMV dissemination by direct virus neutralization or
by cytotoxicity of cells carrying the virus. Antiviral antibodies
have been considered to be important components of the ma-
ternal immune response in the protection against congenital
CMV infection (9, 15) although maternal seropositivity to
CMV prior to pregnancy does not provide absolute protection
against prenatal infection and disease (5). Early studies have
shown that passively acquired maternal anti-CMV antibodies
protected against transfusion-associated CMV infection in the
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immediate postnatal period (61). Passive transfer of CMV-
specific antibodies in multiply transfused preterm infants has
also been shown to be protective in terms of the reduction of
CMV disease (48). Although maternal seropositivity prior to
pregnancy does not provide full protection against prenatal
infection and disease (5), more recent studies have claimed
that treatment of pregnant women with CMV-specific hyper-
immune globulin was effective in prevention of congenital
CMV infection (32). In adult patients, the presence of antiviral
antibodies has been correlated with slower progression of
CMV disease in AIDS patients and transplant patients (7, 45).
Finally, some studies reported that transplant recipients ben-
efited from transfer of CMV-specific antibodies in the post-
transplant period, whereas other studies have shown only min-
imal or no benefit from the transfer of anti-CMV antibodies in
some transplant populations (36). Future studies should define
the optimal conditions for the use of anti-CMV antibodies in
the prevention and treatment of CMV infection.
Due to the HCMV species specificity, several animal models
of HCMV infection, immunobiology, and disease have been
established (4, 53). Among these, infection of mice with
MCMV has been the most frequently used animal model of
HCMV infection (20, 38). We have previously described a
model of MCMV infection of newborn mice and showed
that CNS susceptibility to MCMV diminishes with age since
MCMV infection of newborn, but not adult immunocompetent
mice, results in virus dissemination to the CNS (40, 54). More
recently, we described a model of MCMV-induced encephali-
tis in the developing brain (24). After intraperitoneal (i.p.)
inoculation of the virus into newborn mice, virus disseminated
from peripheral tissues into the CNS, causing the development
of focal, yet widespread, encephalitis defined by mononuclear
cell infiltration. Furthermore, infected animals consistently ex-
hibited developmental and morphological abnormalities in
cerebellum.
Recent studies by Klenovsek et al. demonstrated the protec-
tive capacity of memory B cells. In contrast to previous find-
ings, the investigators showed that memory B cells can prolif-
erate, secrete antiviral antibodies in a T-cell independent
manner, and efficiently control MCMV infection after transfer
into immunodeficient hosts (23). The question arises whether
passive immunization with specific antiviral antibodies has a
protective role during the CMV infection in brain parenchyma.
In the present study, we have described a role of antiviral
antibodies in the control of MCMV infection in brain of new-
born mice. Passive immunization of MCMV-infected newborn
mice with immune serum or MCMV-specific monoclonal an-
tibodies reduced both virus replication and virus-induced pa-
thology in brain tissue, including developmental abnormalities
and specific histopathological lesions.
MATERIALS AND METHODS
Animals, infection conditions, and virus titration. BALB/c (H-2d) mice were
bred under specific-pathogen-free conditions at the Central Animal Facility of
the Faculty of Medicine, University of Rijeka. Handling of animals, experimental
procedures, and administration of anesthesia were performed in accordance with
the guidelines contained in the International Guiding Principles for Biomedical
Research Involving Animals (31a). The Ethics Committee at the University of
Rijeka approved all animal experiments described within this report. Newborn
mice, 6 to 12 h postpartum, were inoculated i.p. with 500 PFU of wild-type (WT)
MCMV (Smith strain, ATCC VR-194 [reaccessioned as VR-1399]). Mice were
anesthetized by i.p. injection of ketamine (2.5 mg/mice) and sacrificed at various
postnatal days (2 to 90). Blood from all groups of animals was collected by
intracardial puncture, heparinized, and divided into cell fraction and plasma by
centrifugation for 4 min at 4,000 rpm. Virus titers in the brain, liver, blood cells,
and plasma were determined using standard plaque assay on mouse embryonic
fibroblasts (8, 39). Individual mice from the same group were also analyzed for
brain histology and cerebellar morphometry.
Histopathology and immunohistochemistry. Serial sagittal sections (4 m
thick) from formalin-fixed, paraffin-embedded brains (following intracardial per-
fusion with phosphate-buffered saline [PBS]) were stained with cresyl violet
(CV). Approximately 80 to 120 slides per animal were stained, depending on the
brain size. Histological evaluation of every 10th slide was performed by two
observers who were unaware of experimental group design. Histopathological
lesions such as inflammatory mononuclear cellular infiltrates, perivascular cuff-
ing, areas of micronodular gliosis, and necrosis were monitored and counted per
slide. Scores were averaged per group of animals and are presented as means 
standard deviations (9, 14).
MCMV-infected cells were visualized by immunohistochemistry by detection
of viral IE1 protein using MCMV-specific monoclonal antibody CROMA 101
(55). Monoclonal antibody (MAb) 97.3 was visualized using biotinylated goat
anti-mouse immunoglobulin G (IgG) antibody (BD Pharmingen, San Diego,
CA). Purkinje cells were visualized using monoclonal anti-calbindin D-28K an-
tibody (Sigma-Aldrich, Munich, Germany). The staining was performed by the
avidin-biotin-peroxidase complex method, using biotinylated goat anti-mouse
IgG as a secondary antibody (BD Pharmingen, San Diego, CA), followed by
detection with an avidin-biotin-peroxidase complex (Roche Applied Science,
Manheim, Germany). Aminoethylcarbazole (Dako Cytomation, Copenhagen
Denmark) or diaminobenzidine (Sigma-Aldrich, Munich, Germany) was used as
the substrate yielding red or brown precipitate. Counterstaining was performed
with Shandon hematoxylin. Slides were analyzed on an Olympus BX40 micro-
scope, and images were acquired by Olympus digital camera (C-3030).
Quantitative PCR. DNA was extracted from mouse newborn brain (10 mg) by
use of a DNA extraction kit (Wizard Promega) and dissolved in 100 l of
rehydration solution. Primers ie3/4fwd (5-TGACTTAAACTCCCCAGGCAA-
3) and ie3/4rev (5-TAGGTGAGGCCATAGTGGCAG-3) were chosen to
amplify a segment of exon 4 of the ie1 gene. A cellular gene was detected with
primers glra1fwd (5-TGCCTGTTCTTTGCAGTCTGT-3) and glra1rev (5-A
GTCGAGTGAAGGGTAACGAGC-3). Reaction mixtures of 20 l consisted
of 4 l of LightCycler FastStart DNA MasterPlus Sybr Green I (Roche Applied
Science), a 0.5 M concentration of each primer, and 5 l of sample DNA. PCR
amplification was done for 45 cycles. Serial dilutions of pGEM-Teasy (Promega)
expressing MCMV ie3/4 and of DNA extracted from murine embryonic fibro-
blasts were used as standards to determine the MCMV genome copy numbers
and the number of cells, respectively. Five standards spanning 5 orders of mag-
nitude were used in duplicate. Brain DNA samples from uninfected mice and
multiple samples without template served as negative controls. Spectra were
acquired in real time and were evaluated with sequence detector software (Ap-
plied Biosystems) and spectral compensation.
Cerebellar morphometry. Images of CV-stained cerebellar sections were ac-
quired by a Pulmix camera (TMC 76S; Japan) mounted on an Olympus BX 40
microscope, and morphometrical measurements were performed with ISSA soft-
ware (VAMS, Zagreb, Croatia) and IPLab (Scanalytics, Inc., Fairfax, VA) soft-
ware. Thickness of the cerebellar external granular layer (EGL) was measured at
six points along the primary cerebellar fissure. The number of Purkinje cells was
counted along 500 m at both sides of the primary fissure.
MCMV immune serum and MAb 97.3 preparation. Immune serum was col-
lected from adult BALB/c mice infected with 2  105 PFU of WT MCMV for 3 to
4 months. Control serum was collected from uninfected age-matched BALB/c mice.
MCMV-specific MAb 97.3 (IgG2a) was generated from MCMV-infected C57BL/6
mice challenged with 2 g of MCMV particles intravenously 4 days before fusion
essentially as described previously (11). Supernatant from growing hybridoma was
used for an in vitro neutralization assay using the MCMV157luc virus (23). Super-
natant showing strong neutralizing activity was further characterized for antigen
specificity. The M55 gene encoding gB of WT MCMV (38) was cloned into the
plasmid pcDNA3 and used in indirect immunofluorescence analysis after transient
expression of the protein in Cos7 cells. Clone 97.3 showed strong reactivity, in
contrast to control cells expressing unrelated MCMV glycoproteins that were neg-
ative in this assay. Ascites was produced by i.p. injection of 106 97.3 hybridoma cells
into pristane-primed mice and purified with 30% ammonium sulfate. Protein con-
centration was determined by enzyme-linked immunosorbent assay.
Determination of neutralizing titer of anti-MCMV serum and MAbs. Neutral-
ization assays were performed as described previously (46). In brief, the titer of
neutralizing antibody in serum of latently infected mice was defined as the
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maximal plaque reduction in a conventional plaque reduction assay. A total of
102 PFU of MCMV in 0.1 ml of plaque assay medium (3% Dulbecco’s modified
Eagle’s medium) was incubated on ice for 30 min with 0.1 ml of serial dilutions
of immune serum or MAbs, followed by plaque assay.
Neutralization units of MAb 97.3 were defined from in vitro neutralization
assay as micrograms of MAb used to neutralize 100% of 102 virus PFU in a
conventional plaque reduction assay (12).
In vivo inoculation of immune serum and MAb 97.3. Newborn mice infected
with MCMV were randomized and inoculated i.p. with immune serum, control
serum (100 l of either), or anti-MCMV MAb 97.3, isotype-matched control
antibodies (IgG2a) (100 g of either), or PBS (100 l). The antibodies were
administrated on day 5 or day 9 postinfection (p.i.).
Statistical evaluation. Results from different groups of mice were compared by
a Mann-Whitney exact rank sum test using Statistica software (version 7.0). For
all analyses the significance level was set at a P value of 0.05.
RESULTS
MCMV replication kinetics and spread within the newborn
brain parenchyma. We have recently shown that MCMV infec-
tion of newborn mice results in brain infection, inflammation, and
developmental abnormalities of the cerebellum (24). Here, we
used MCMV infection of newborn mice to assess the protective
capacity of antiviral antibodies with respect to virus replication
and related neuropathology. In agreement with previously de-
scribed results, we observed that i.p. injection of MCMV in new-
born mice results in peak virus replication within the brain around
day 11 p.i., and clearance of replicating virus occurs around day
17 p.i. (Fig. 1A). Notably, virus detection in the liver preceded the
virus detection in the brain although the kinetics of virus replica-
tion were similar in both organs (Fig. 1B).
Immunohistological studies at the peak of virus replication
(day 11 p.i.) revealed widespread distribution of infected cells
with no particular preference to any region or cell type within
the brain. According to nuclear staining for IE1 MCMV pro-
tein pp89, infected cells were detected in the cerebral cortex,
hippocampus, olfactory bulb, thalamus, colliculi, and cerebel-
lum (Fig. 1C to G). Virus-infected cells were also detected in
brain stem, meninges, ependyma, and choroid plexuses of the
FIG. 1. Kinetics of virus replication and spread in brain of MCMV-infected newborn mice. MCMV replication in the brains (A) and livers
(B) of newborn mice. Mice were inoculated i.p. with 500 PFU of MCMV, 6 to 12 h after birth, and viral titers in their organs were assessed at
various time points p.i. Productive infection in the brains was detected starting from day 7 p.i. and was visible through day 17 p.i. Titers of virus
in individual mice (circles) and median values (horizontal bars) are shown. DL, detection limit. (C to G) MCMV antigen expression in the brains
of newborn mice. Scattered infected cells located in the cerebral cortex, hippocampus, olfactory bulb, colliculi, and cerebellar cortex of infected
mice are shown, as indicated on the figure, at day 11 p.i. Immunohistochemical staining with MCMV IE1-specific MAbs reactive with MCMV IE1
protein is shown. Magnification, 20 (C, E, and F) and 40 (D and G).
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ventricles (data not shown). Of note, although this type of
infection led to readily observable abnormalities in the devel-
opment of entire regions of the brain, such as cerebellum, foci
of infected cells in the CNS were solitary and infrequent.
Anti-MCMV serum reduces MCMV titer in brains of in-
fected newborn mice. To determine the effect of antiviral an-
tibodies on virus replication in the MCMV-infected brain,
newborn BALB/c mice (day 0) were infected with 500 PFU of
MCMV by i.p. inoculation and treated systemically with im-
mune serum at days 5 or 9 p.i. Control animals received non-
immune mouse serum or PBS. Mice were sacrificed on days 11
and 14 p.i., and virus titers in brain and liver were determined.
In agreement with previous results, all control mice given PBS
showed significant virus replication on days 11 and 14 p.i., and
injection of nonimmune serum did not affect the virus replica-
tion, findings that were similar to mice injected with PBS only.
In contrast, the majority of mice inoculated with MCMV im-
mune serum had no detectable replicating virus in the brain
when the immune serum was given on day 5 p.i. (Fig. 2A).
Although mice that received immune serum on day 9 p.i.
showed only moderate protection at day 11 p.i., these animals
efficiently controlled the infection in the CNS by day 14 p.i.
when no infectious virus could be detected in the brain, con-
firming the antiviral activity of immune serum (Fig. 2B). The
protective capacity of the immune serum was not restricted to
the brain since serum administration also abrogated virus rep-
lication in the liver (data not shown). Finally, to rule out the
unlikely possibility that residual antibody present in the paren-
chyma could have reduced virus titers in the infectivity assays,
we also assayed brain tissue from treated animals for viral
DNA by quantitative PCR. Results from assays of brain tissue
from p.i. days 11 and 14 in mice treated with immune serum
even on day 9 p.i. revealed reductions in viral genome copy
numbers on day 14 p.i. of 1 log compared to tissue from mice
given PBS only (Fig. 2C). These results demonstrated a strong
protective capacity of immune serum in MCMV-infected new-
born mouse brain that was associated with the reduction of
both infectious virus and viral genome copy number. The ob-
served differences in the protective effect of antibodies on the
titers of infectious virus compared to viral DNA load in the
brain was not unexpected since the quantitative PCR method
allows detection of not only DNA of infectious virus but also
the DNA in cells containing nonreplicating viral genome, in-
cluding cells that populate the developing CNS such as infil-
trating microglia. Immunohistochemical analysis of MCMV-
infected newborn mice treated with immune serum confirmed
the results obtained by virus titration and showed a reduced
number of infected cells expressing viral IE1 protein (data not
shown). Infected cells, although fewer in number, showed the
same pattern of distribution in the brains of mice treated with
immune serum as control mice.
Anti-MCMV MAbs reduce virus replication in newborn
mouse brains. The efficacy of serum transfer into MCMV-
infected newborn mice suggested that antibodies can control
virus replication in the brain. To exclude an involvement of
other immune serum components in addition to virus-specific
antibodies, we tested the capacity of virus-specific MAbs to
limit virus replication in the brain. MCMV-infected newborn
BALB/c mice were injected i.p. with virus-neutralizing MAb
97.3 specific for MCMV gB (data not shown). The neutralizing
capacity of this MAb was determined in vitro (see Fig. 1 posted
at http://www.medri.hr/jstipan/data), and each mouse
received 12.5 neutralizing units of purified MAbs i.p. Control
animals received an irrelevant isotype-matched MAb. Virus
-specific MAbs were also protective in vivo (Fig. 3). Mice
injected with MAb 97.3 showed decreased viral loads in the
FIG. 2. Immune serum limits the recovery of the infectious virus
and reduces the load of viral genomes in the brains of MCMV-infected
newborn mice. MCMV-infected newborn BALB/c mice received 100
l of immune serum (black circles), control serum (gray circles), or
equal amount of PBS (open circles) on day 5 (A) or day 9 p.i. (B).
Virus titers were determined in the brain on days 11 and 14 p.i.
(C) Viral DNA load was determined by quantitative PCR in the brains
of mice receiving immune serum (black circles) or PBS (open circles)
at day 9 p.i. on days 11 and 14 p.i. Horizontal bars represent the
median value. DL, detection limit.
FIG. 3. Anti-MCMV MAb 97.3 limits virus recovery from the
brains of MCMV-infected newborn mice. MCMV-infected BALB/c
mice received 100 g of 97.3 (F) or control MAb of IgG2a isotype (E)
on day 5 (A) or day 9 p.i. (B) Virus titers were determined in the brain
on days 11 and 14 p.i. Titers of virus in individual mice (circles) and
median values (horizontal bars) are shown. DL, detection limit.
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brain of approximately 1 log compared to control animals
treated with isotype-matched MAbs. However, in comparison
to the protective capacity of MCMV-specific immune serum,
MAbs did not limit virus replication below the level of
detection in our assays (Fig. 3A and B).
The 97.3 MAbs were visualized in the parenchyma of the
brains of infected animals treated on day 9 p.i. by immunohis-
tochemistry. The passively transferred antibodies were de-
tected surrounding the brain endothelium and, in some cases,
around neurons, suggesting that passively acquired antibodies
could enter the CNS of MCMV-infected young mice (see Fig.
2 posted at http://www.medri.hr/jstipan/data). Whether the
effector function of passively acquired anti-MCMV antibodies
is at the level of endothelium or within the infected
parenchyma cannot be resolved in these experiments and will
require additional study.
Protective capacity of MCMV-specific immune serum and
MAbs correlates with reduction of virus-induced brain pathol-
ogy. Next, we analyzed the effects of passive transfer of anti-
viral antibodies on the inflammatory response in brains of
MCMV-infected newborn mice. As described previously (24,
25), inflammatory lesions were observed in all parts of the
brain of infected animals. These histopathological lesions var-
ied in size, quantity, and distribution. The observed lesions
included edema, infiltrates of mononuclear cells, micronodular
gliosis, perivascular cuffing, and reactive gliosis. In some cases
cortical involvement dominated whereas in other cases lesions
were equally divided in gray and white matter.
The first pathological lesions observed on day 7 p.i. consisted
of mononuclear cell infiltrations, localized to the meninges and
choroid plexus (Fig. 4A and D). Inflammatory lesions were
observed within the brain parenchyma by day 11 p.i. (Fig. 4B to
F). The kinetics of brain inflammatory lesions resembled the
kinetics of detection of infectious virus, but the peak number of
lesions and the overall kinetics of their appearance were de-
layed in comparison to the kinetics of virus replication in the
CNS. The productive infection terminated by day 17 p.i., but a
focal encephalitic response persisted even by day 80 p.i. (Fig.
4G). To assess whether the protective capacity of MAbs influ-
ences the number and the severity of inflammatory lesions, we
infected newborn BALB/c mice and subsequently treated the
animals with immune serum or MAbs. Histological examina-
tion revealed a dramatic reduction in the number of his-
topathological lesions in brains of mice treated with immune
serum or MAbs in contrast to control animals. Antibody trans-
fer on day 5 p.i. resulted in a significant reduction of the
number of inflammatory lesions by day 14 p.i., which was also
observed through day 21 p.i. (Fig. 5A). Likewise, the transfer
of MAbs resulted in pronounced reduction of inflammatory
lesions in the infected brains (Fig. 5B), arguing that antiviral
antibodies could limit not only virus replication in the CNS but
also the MCMV-induced disease in the brain.
Altogether, the results confirmed that the transfer of antivi-
ral antibodies reduced the virus load and, even more impor-
tantly, the development and the persistence of inflammatory
pathology in the brain tissue.
Administration of anti-MCMV antibodies prevents develop-
mental brain abnormalities in MCMV-infected newborn mice.
MCMV infection of the CNS has been shown to alter the
normal postnatal development of the cerebellum, which is
manifested by delayed migration of neurons from the cerebel-
lar EGL into deeper parts of cerebellar cortex (24). To deter-
mine if the passive transfer of antiviral antibodies would also
reduce cerebellar developmental abnormalities in CMV infec-
tion of the CNS, we compared the EGL thickness between
groups of animals that received immune serum, control serum,
or MCMV-specific MAbs on day 5 p.i. Mice treated with con-
trol serum manifested increased EGL thickness, similar to our
previous observation in MCMV-infected mice (24). In mice
treated with anti-MCMV immune serum or MAbs, the EGL
thickness was reduced to levels comparable to those observed
in uninfected control mice (Fig. 6B and C). Also, mice treated
with immune serum or MAbs exhibited cerebellar area that
was similar to that of the control, uninfected mice, whereas
MCMV-infected mice receiving control serum exhibited a sig-
nificantly reduced cerebellar area on days 11 and 14 p.i. (Fig.
6A). Immunohistological analysis using anti-calbindin MAbs
specific for Purkinje cells demonstrated defective arborization
and reduced numbers of these cells in the MCMV-infected
cerebellum. Antibody-treated mice showed a significant reduc-
tion or even absence of these abnormalities (Fig. 6D).
These results demonstrated that MCMV-specific immune
serum and MAbs reduced the viral load in the brain and as a
consequence led to a decrease in the degree of inflammatory
changes associated with this virus infection of the CNS. In
addition, the decrease in levels of virus replication and inflam-
mation was associated with lessening of the developmental
abnormalities associated with this infection of the CNS in
MCMV-infected newborn mice.
DISCUSSION
Congenital HCMV infection is an important public health
issue, primarily due to long-term sensorimotor deficits that are
observed after infection of the developing nervous system (28).
The pathogenesis of CMV encephalitis is still insufficiently
defined because of the limited number of autopsy cases with a
comprehensive description of the pathological changes de-
tected in infected infants. Since CMV can readily infect endo-
thelial cells (13, 42), it has been postulated that a virus-induced
vasculitis might be responsible for loss of vascular supply to
regions of the developing brain, resulting in maldevelopment
(30). Other investigators have postulated a direct cytopathic
effect of CMV on developing neurons and glial cells (58). The
immune response to CMV infection may also contribute to the
pathogenesis of CNS disease. Specifically, elaboration of im-
mune responses in this particular tissue may have immuno-
pathological consequences as described for CNS infections
with other viruses (17, 31, 60). Our recent studies indicate that
infiltrating CD8 T cells in MCMV-infected newborn brain
mediate their antiviral activity mostly via a noncytolytic
pathway (1). This finding could in part explain the histolog-
ical characteristics of nonnecrotizing encephalitis following
MCMV infection in newborn mouse brain (24). Importantly,
the histopathology observed in the brains of mice infected with
MCMV as newborns resembles findings reported in autopsied
cases of human congenital CMV infections (33).
Antiviral antibodies are powerful effector functions for virus
neutralization and prevention of virus spread. Although not
required for resolution of primary infection, antibodies have
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proven to be essential for prevention of virus dissemination
after recurrence or reinfection (21, 35). Using the mouse
model of CMV-induced encephalitis, we tested the capacity of
antiviral antibodies to reduce virus replication in brain and
CMV-related brain pathology in newborn mice. We have dem-
onstrated that anti-MCMV antibodies not only lowered the
burden of infectious virus present in brain tissue but also dra-
matically reduced the associated neuropathology. Mice that
received antiviral antibodies exhibited fewer and more limited
histopathological lesions and had improved postnatal develop-
ment of cerebellum compared to control infected mice.
Antibody-mediated neutralization of viruses has been exten-
sively studied in vitro, but the precise mechanism that provides
protection against viral infection in vivo still remains largely
uncharacterized. Several studies have suggested that passive
immunization reduces CMV infection. High levels of virus-
neutralizing antibodies were associated with delayed progres-
sion of HCMV-induced retinitis in AIDS patients, and passive
FIG. 4. Histopathological lesions in brains of MCMV-infected newborn mice. CV staining of different brain regions show acute meningitis
(A) and mononuclear cell infiltration in choroids plexus (D) on day 7 p.i., mononuclear cell infiltration in cerebellar cortex (B), perivascular cuffing
in hippocampus (C) on day 11 p.i., and edema (E) and glial node (F) in hindbrain on day 14 p.i. Magnification, 20 (A to E) and 40 (F and
insets). Histopathological lesions were observed in brain parenchyma even at day 80 p.i. (G).
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transfer of antiviral antibodies into solid organ transplant re-
cipients has been correlated with improved outcome and re-
duced severity of HCMV infections (7, 47). Although the idea
is controversial, it has recently been claimed that adoptive
transfer of virus-neutralizing antibodies to women undergoing
primary infection during pregnancy limited the rate of intra-
uterine transmission of HCMV to the developing fetus (32),
whereas other studies have shown that antibodies play little, if
any, role in the protection against virus-induced neurologic
damage in the infected fetus following primary maternal infec-
tion (5). However, maternal preconceptual immunity, as mea-
sured by the presence of antiviral antibodies, does appear to
reduce the rates of congenital CMV infection in subsequent
pregnancies in both humans and the guinea pig model of hu-
man CMV infection (9, 15).
In animal models antibodies have been shown to be essential
for virus clearance from infected brain (16). The mechanism of
antibody-mediated clearance of the virus in this model remains
incompletely defined. Both virus-neutralizing and -nonneutral-
izing antibodies could affect virus clearance, and immunoglob-
ulin subclass appears important for virus clearance (56). A
series of experiments has been consistent with these findings,
showing that nonneutralizing antibodies (as determined in in
vitro assays) can protect mice from lethal neurovirulent Sindbis
virus encephalitis (50). Although we have not extended our
studies to include MAbs of different subclasses and different
neutralization capacities, in this report we show that the ad-
ministration of antibodies with virus-neutralizing activity re-
duced the number of infected cells detected in the CNS. In the
current study we also observed that the neutralizing capacity of
a MAb in vitro does not necessarily correlate with its antiviral
activity in vivo. In mice that received antibodies, the distribu-
tion of virus-infected cells was similar to findings in control
mice, indicating that antiviral antibodies did not alter the pat-
tern of virus infection of the CNS but more likely reduced the
amount of the virus in the brain. We also observed a lower viral
burden in brains of mice that received antibodies on day 5 p.i.,
supporting the possibility that antibody-mediated neutraliza-
tion of cell-free virus in blood of newborn mice could effec-
tively limit the access of MCMV to CNS. It is important to point
out that both cell-associated and free virus could be detected in
blood of newborn mice (see Fig. 3 posted at http://www.medri
FIG. 5. Protective effect of immune serum or anti-MCMV MAbs
on the development of histopathology in infected newborn brain.
MCMV-infected mice received 100 l of immune serum and control
serum (A) or 100 g of MAb 97.3 and control antibody (B) on day
5 p.i. Histopathology was evaluated by counting the lesions in CV-
stained slides of infected brains on days 14, 17, and 21 p.i. Each bar is
representative of a minimum of three animals per group. *, P  0.05.
FIG. 6. Antiviral antibodies prevent MCMV-induced developmental ab-
normalities in the cerebella of newborn mice. (A) Cerebellar area in infected
and uninfected newborn mice. Mice treated with immune serum on day 5 p.i.
show significant increase (*, P  0.05) in cerebellar area compared to un-
treated infected mice (days 11 and 14 p.i.). Mice treated with MAb 97.3 on
day 5 p.i. show improvement in cerebellar area but without statistically sig-
nificant difference to control infected mice. (B) EGL thickness in MCMV-
infected and uninfected cerebellum. Mice treated with immune serum on day
5 p.i. show significantly decreased (*, P 0.05) EGL thickness on day 11 p.i.
compared to untreated infected mice. Mice treated with MAb 97.3 also have
decreased EGL thickness but with no statistical difference relative to control
infected animals. (C) EGL thickness in MCMV-infected cerebellum treated
with control serum (left) or immune serum (right) on day 12 p.i. is shown in
CV-stained sections. Magnification, 20. (D) Purkinje cell alignment in
MCMV-infected cerebellum is modified by treatment with antiviral antibod-
ies. MCMV-infected cerebellum (left panel) and cerebellum of infected,
immune serum-treated mice (right panel) are shown. Anti-calbindin MAb
was used for immunohistochemical staining. Magnification, 40.
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.hr/jstipan/data). This finding suggests that antibodies
applied on day 5 p.i. may prevent virus spread into developing
brain by both direct neutralization of the virus or by
mechanisms which clear virus-infected cells such as antibody
-dependent cellular cytotoxicity. However, antibodies given to
infected mice on day 9 p.i., a time that coincided with the peak
of virus replication in the brain, were also protective,
suggesting that neutralization of cell-free virus in the blood of
infected animals and limitation of seeding the brain were not
the only mechanisms of antiviral activity in this model and that
antiviral antibodies could be functioning within the CNS to
limit virus spread and/or replication as shown for other viruses
(57). Recent studies show that antibodies are capable of
crossing the blood-brain barrier after i.p. inoculation (44). In
animals that received MAbs, we detected antibodies around
blood vessel endothelium as well as around neuronal cells,
suggesting that antibodies infiltrate the CNS (see Fig. 4
posted at http://www.medri.hr/jstipan/data). Although the
mechanism of transfer of antiviral IgG antibodies into the CNS
in these young animals has not been fully determined,
preliminary studies using Evans blue to document leakage of
the blood-brain barrier did not indicate that diffusion of IgG
into the brain secondary to disruption of the blood-brain
barrier contributed to the antiviral activity in CNS (data not
shown). Other mechanisms of IgG transport such as facilitated
transport through the endothelium or perhaps binding to
mononuclear cells through interactions with Fc remain
potential explanations (37).
We also found that adoptive transfer of antibodies limited
development of brain lesions. Histopathological findings in
congenital HCMV infections include ventriculoencephalitis
consisting of periventricular necrosis, intraventricular hemor-
rhage, and calcifications (3, 33). In a murine model of congen-
ital CMV infection, widespread encephalitis is a common find-
ing following direct intracranial inoculation of the virus (10,
25). In this model histopathological lesions were comprised of
infected cells which were associated with infiltration of inflam-
matory cells, including mono- and polymorphonuclear leuko-
cytes, or activation of resident microglia (25, 59). In our model
we also observed histopathological lesions characteristic of me-
ningoencephalitis. The first observed lesion was leptomeningi-
tis, whose appearance coincided with detection of the virus in
the brain, whereas lesions in the parenchyma appeared later.
The most obvious response in the brain parenchyma was
perivascular cuffing composed of mononuclear cells. In con-
trast, glial nodules represented a major local response. Lesions
persisted even when replicating virus was no longer detected in
the brain, suggesting that immune cells resided in the brain
parenchyma despite the termination of productive virus infec-
tion. We have recently shown that CD8 T lymphocytes are a
predominant immune cell population in MCMV-infected new-
born brain and are present in the CNS after the resolution of
an acute infection (1). In infected newborn mice that received
antibody treatment, histopathological findings in brain tissue
showed distinctive differences among the extent and severity of
parenchyma destruction compared to control mice. Adminis-
tration of immune serum reduced both the number and sever-
ity of inflammatory lesions. Moreover, treatment with immune
serum shortened the interval required for reestablishment of
the normal brain architecture in infected mice.
Newborn mice infected with MCMV exhibit altered cerebel-
lar morphogenesis in terms of foliation delay, impaired mor-
phology of Purkinje cells, and persistence of EGL (24). Anti-
body transfer into MCMV-infected newborn mice resulted in
improved development of infected cerebellum. These mice
showed EGL thickness comparable to uninfected mice, normal
Purkinje cell morphology, and increased cerebellar area com-
pared to untreated infected mice. Therefore, antiviral antibod-
ies also appeared to be effective in preventing virus-associated
developmental abnormalities and altered neuronal migration,
suggesting that limiting virus replication and presumably the
host inflammatory response also decreased the developmental
alterations associated with virus replication in the CNS.
In summary, this experimental model may provide insight into
the pathogenesis of CMV injury and support the efforts toward
devising optimal antibody-based therapeutic approaches.
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